With a record 45 clinical trials either ongoing or starting up in 2016, research coordinators and principal investigators throughout the Therapeutics Development Network took time out in San Antonio recently to discuss clinical research and put attendees through boot camp.
Site Search
Hear from John P. Clancy, M.D., the first plenary speaker at this year's NACFC, about recent advances in personalized medicine, which could allow clinicians to better tailor treatment to the individual with CF.
The Foundation hosted a small conference that brought together CF scientists, clinical researchers, and biotechnology and pharmaceutical industry representatives. Learn more and watch a short video of attendees sharing their thoughts about the progress we are making in CF research.
PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Dr. Skach discusses the latest advances in CF research and exciting new approaches to address the underlying cause of the disease.
The Cystic Fibrosis Foundation’s Whole Genome Sequencing (WGS) project contains WGS data from over 5,000 people with cystic fibrosis in the United States that is linked with data from the CF Foundation Patient Registry.
The patient-centered outcomes research (PCOR) training manual provides discrete steps, tools, and resources that CF Center research teams can take to integrate and maintain patient/caregiver-partners in CF research.
This award is part of the Cystic Fibrosis Foundation’s Physician Scientist Training Program and is designed to introduce residents to cystic fibrosis research with the goal to develop and maintain interest in a career in CF research or as a CF care provider.
This award program is intended to fund training for physicians interested in developing expertise in the endocrinologic care of patients with cystic fibrosis.
The Cystic Fibrosis Foundation is requesting applications with a Letter of Intent for innovative, multi-site quality improvement projects that aim to test tools and processes facilitating remote cystic fibrosis care delivery.